Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Bone Sarcoma: early-phase trial registry

5 of 9 indexed Bone Sarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Bone Sarcoma: 9 US clinical trials tracked, 5 recruiting.

Bone Sarcoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition bone-sarcoma

OPEN 5 | RECR 56% | LATE 0 | EARLY 5 | RANK #1916 | SPON 2

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Bone Sarcoma (this)56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Bone Sarcoma

Bone Sarcoma lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bone Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bone Sarcoma is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Bone Sarcoma research.

    M.D. Anderson Cancer Center accounts for 2 of 9 trials (22.2%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Bone Sarcoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.

  4. Bone Sarcoma splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22

Open and recent trials

9 total, page 1 of 1

RECRUITING 300 participants

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

Memorial Sloan Kettering Cancer Center

NCT03442465

RECRUITING 72 participants

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

Mayo Clinic

NCT05033288

RECRUITING NA 60 participants

Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma

Memorial Sloan Kettering Cancer Center

NCT06129903

RECRUITING 50 participants

Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma

Mayo Clinic

NCT06409013

RECRUITING Phase 1 40 participants

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

M.D. Anderson Cancer Center

NCT05621668

ACTIVE NOT RECRUITING Phase 2 30 participants

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

NCT03449108

ACTIVE NOT RECRUITING Early Phase 1 30 participants

Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

University of Iowa

NCT04634227

ACTIVE NOT RECRUITING Phase 1 14 participants

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

NCT04616248

COMPLETED Phase 2 144 participants

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Sarcoma Alliance for Research through Collaboration

NCT02301039

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Named interventions

Most-linked intervention names on Bone Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
2 trials
Pembrolizumab Drug
2 trials
Ascorbate Drug
1 trials
Recombinant Flt3 Ligand Biological
1 trials
Autologous Tumor Infiltrating Lymphocytes LN-145-S1 Biological
1 trials
Autologous Tumor Infiltrating Lymphocytes LN-145 Biological
1 trials
Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Biological
1 trials
attIL2-T cells Drug
1 trials

US sites by state

Facility locations filed on Bone Sarcoma trials. A trial with sites in several states counts in each.

Texas 3 trials
New York 3 trials
Minnesota 3 trials
New Jersey 2 trials
Florida 2 trials
California 2 trials
Pennsylvania 1 trials
Oregon 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bone Sarcoma page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bone Sarcoma condition card totals 9 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.